Subtype
Astrocytic Tumor
CI-CAN-00001839Explore in graph →
Non-malignant507 active trials2 approved drugs67 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00001839Explore in graph →
Clinical trials
1,861 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01225510 | A Trial Of PF-04856884 In Patients With Recurrent Glioblastoma | withdrawn | Phase 2 | 0 | PfizerINDUSTRY | 0 | Mar 11, 2015 | clinicaltrials |
| NCT01582516 | Safety Study of Replication-competent Adenovirus (Delta-24-rgd) in Patients With Recurrent Glioblastoma | completed | Phase 1 / Phase 2 | 20 | Erasmus Medical CenterOTHER | 1 | Mar 9, 2015 | clinicaltrials |
| NCT00179907 |
| A Phase I/II Study of the Photon Radiosurgery System |
| completed |
| Phase 1 / Phase 2 |
| 35 |
| Ann & Robert H Lurie Children's Hospital of ChicagoOTHER |
| 1 |
| Mar 2, 2015 |
| clinicaltrials |
| NCT00723827 | Temodal (Temozolomide) Post Marketing Surveillance Protocol (Study P05557AM2) | completed | — | 682 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Jan 30, 2015 | clinicaltrials |
| NCT00734682 | A Phase I Trial of Nanoliposomal CPT-11 (NL CPT-11) in Patients With Recurrent High-Grade Gliomas | completed | Phase 1 | 34 | University of California, San FranciscoOTHER | 1 | Jan 7, 2015 | clinicaltrials |
| NCT01131234 | Gamma-Secretase Inhibitor RO4929097 and Cediranib Maleate in Treating Patients With Advanced Solid Tumors | completed | Phase 1 | 20 | National Cancer Institute (NCI)NIH | 1 | Dec 23, 2014 | clinicaltrials |
| NCT01378481 | High-Dose Vorinostat and Fractionated Stereotactic Body Radiation Therapy in Treating Patients With Recurrent Glioma | terminated | Phase 1 | 30 | National Cancer Institute (NCI)NIH | 1 | Dec 23, 2014 | clinicaltrials |
| NCT02227901 | Tipifarnib, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma Multiforme | completed | Phase 1 | 19 | National Cancer Institute (NCI)NIH | 1 | Dec 23, 2014 | clinicaltrials |
| NCT01124539 | Study of AR-67 in Adult Patients With Recurrence of Glioblastoma Multiforme (GBM) or Gliosarcoma | unknown | Phase 2 | 58 | Arno TherapeuticsINDUSTRY | 2 | Dec 9, 2014 | clinicaltrials |
| NCT01115491 | A Study of Bevacizumab and Extended Treatment of Temozolomide in Patients With Recurrent Glioblastoma Multiforme | completed | Phase 2 | 32 | Hoffmann-La RocheINDUSTRY | 1 | Dec 8, 2014 | clinicaltrials |
| NCT00024570 | Interstitial Infusion of IL13-PE38QQR Cytotoxin in Recurrent Malignant Glioma | completed | Phase 1 / Phase 2 | 60 | INSYS Therapeutics IncINDUSTRY | 1 | Nov 14, 2014 | clinicaltrials |
| NCT00525525 | Study of Bevacizumab Plus Temodar and Tarceva in Patients With Glioblastoma or Gliosarcoma(AVF4120s) | completed | Phase 2 | 74 | University of California, San FranciscoOTHER | 1 | Nov 14, 2014 | clinicaltrials |
| NCT00761280 | Efficacy and Safety of AP 12009 in Patients With Recurrent or Refractory Anaplastic Astrocytoma or Secondary Glioblastoma(SAPPHIRE) | terminated | Phase 3 | 27 | Isarna Therapeutics GmbHINDUSTRY | 16 | Nov 14, 2014 | clinicaltrials |
| NCT01088763 | Gamma-Secretase Inhibitor RO4929097 in Treating Young Patients With Relapsed or Refractory Solid Tumors, CNS Tumors, Lymphoma, or T-Cell Leukemia | terminated | Phase 1 | 129 | National Cancer Institute (NCI)NIH | 2 | Nov 5, 2014 | clinicaltrials |
| NCT00689221 | Cilengitide, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma and Methylated Gene Promoter Status(CENTRIC) | completed | Phase 3 | 545 | EMD SeronoINDUSTRY | 2 | Nov 4, 2014 | clinicaltrials |
| NCT00884416 | Sorafenib in Newly Diagnosed High Grade Glioma | completed | Phase 1 | 17 | University Hospital, GenevaOTHER | 1 | Nov 4, 2014 | clinicaltrials |
| NCT00576641 | Immunotherapy for Patients With Brain Stem Glioma and Glioblastoma | completed | Phase 1 | 22 | Cedars-Sinai Medical CenterOTHER | 1 | Oct 30, 2014 | clinicaltrials |
| NCT00411619 | Everolimus (RAD001) Therapy of Giant Cell Astrocytoma in Patients With Tuberous Sclerosis Complex | completed | Phase 1 / Phase 2 | 28 | Children's Hospital Medical Center, CincinnatiOTHER | 1 | Oct 20, 2014 | clinicaltrials |
| NCT00960492 | Safety Study of XL184 (Cabozantinib) in Combination With Temozolomide and Radiation Therapy in the Initial Treatment of Adults With Glioblastoma | completed | Phase 1 | 26 | ExelixisINDUSTRY | 1 | Sep 22, 2014 | clinicaltrials |
| NCT01006044 | Efficacy & Safety of Autologous Dendritic Cell Vaccination in Glioblastoma Multiforme After Complete Surgical Resection | completed | Phase 2 | 26 | Clinica Universidad de Navarra, Universidad de NavarraOTHER | 1 | Sep 3, 2014 | clinicaltrials |
| NCT00616005 | Ph. II Treatment of Adults w Primary Malignant Glioma w Irinotecan + Temozolomide | completed | Phase 2 | 41 | Duke UniversityOTHER | 1 | Aug 18, 2014 | clinicaltrials |
| NCT01380782 | BIBF 1120 for Recurrent High-Grade Gliomas | completed | Phase 2 | 37 | Patrick Y. Wen, MDOTHER | 1 | Aug 18, 2014 | clinicaltrials |
| NCT00941460 | Comparison of Two Dosing Regimens of Temozolomide in Patients With Progressive or Recurrent Glioblastoma(DIRECTOR) | completed | Phase 2 | 105 | Prof. Dr. Wolfgang WickOTHER | 3 | Aug 15, 2014 | clinicaltrials |
| NCT00897377 | Treatment Strategy for Low-grade Gliomas | terminated | Phase 3 | 500 | Sun Yat-sen UniversityOTHER | 1 | Aug 5, 2014 | clinicaltrials |
| NCT00611728 | Ph I SU011248 + Irinotecan in Treatment of Pts w MG | completed | Phase 1 | 25 | Duke UniversityOTHER | 1 | Jul 21, 2014 | clinicaltrials |
| NCT00609999 | Ph I Dasatinib + Erlotinib in Recurrent MG | completed | Phase 1 | 47 | Duke UniversityOTHER | 1 | Jul 16, 2014 | clinicaltrials |
| NCT00612989 | Ph I 5-day Temozolomide + O6-BG in Treatment of Pts w Recurrent / Progressive GBM | completed | Phase 1 | 42 | Duke UniversityOTHER | 1 | Jul 16, 2014 | clinicaltrials |
| NCT00613093 | Ph. II Temozolomide + O6-BG in Treatment of Pts w Temozolomide-Resistant Malignant Glioma | completed | Phase 2 | 67 | Duke UniversityOTHER | 1 | Jul 9, 2014 | clinicaltrials |
| NCT00946335 | ABT-888 and Temozolomide in Treating Young Patients With Recurrent or Refractory CNS Tumors | completed | Phase 1 | 31 | National Cancer Institute (NCI)NIH | 1 | Jul 9, 2014 | clinicaltrials |
| NCT00589095 | Early Detection of Glioblastoma Multiforme (GBM) Treatment Responses Using Multiple Magnetic Resonance Modalities | terminated | — | 5 | Yale UniversityOTHER | 1 | Jul 2, 2014 | clinicaltrials |
| NCT02055196 | Genetically Modified Stem Cells and Irinotecan Hydrochloride in Treating Patients With Recurrent High-Grade Gliomas | withdrawn | Phase 1 | 0 | City of Hope Medical CenterOTHER | 1 | Jun 2, 2014 | clinicaltrials |
| NCT00093613 | Sorafenib in Treating Patients With Recurrent or Progressive Malignant Glioma | completed | Phase 1 | 47 | National Cancer Institute (NCI)NIH | 1 | May 30, 2014 | clinicaltrials |
| NCT00650923 | Aflibercept, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed or Recurrent Glioblastoma Multiforme, Gliosarcoma, or Other Malignant Glioma | completed | Phase 1 | 61 | National Cancer Institute (NCI)NIH | 1 | May 30, 2014 | clinicaltrials |
| NCT00042991 | Gefitinib and Radiation Therapy in Treating Children With Newly Diagnosed Gliomas | completed | Phase 1 / Phase 2 | 69 | National Cancer Institute (NCI)NIH | 1 | May 28, 2014 | clinicaltrials |
| NCT00095940 | Lapatinib in Treating Young Patients With Recurrent or Refractory Central Nervous System Tumors | completed | Phase 1 / Phase 2 | 52 | National Cancer Institute (NCI)NIH | 1 | May 23, 2014 | clinicaltrials |
| NCT00238303 | Vorinostat in Treating Patients With Progressive or Recurrent Glioblastoma Multiforme | completed | Phase 2 | 103 | National Cancer Institute (NCI)NIH | 1 | May 23, 2014 | clinicaltrials |
| NCT01169415 | Effects of Steroid Tapering on Functional Capacity and Neurocognition | withdrawn | N/A | 0 | Duke UniversityOTHER | 0 | May 19, 2014 | clinicaltrials |
| NCT01403285 | Peptide-based Glioma Vaccine IMA950 in Patients With Glioblastoma | terminated | Phase 1 | 6 | Immatics Biotechnologies GmbHINDUSTRY | 1 | May 19, 2014 | clinicaltrials |
| NCT00641706 | Vorinostat and Bortezomib in Treating Patients With Progressive, Recurrent Glioblastoma Multiforme | completed | Phase 2 | 44 | National Cancer Institute (NCI)NIH | 1 | May 14, 2014 | clinicaltrials |
| NCT00492089 | Bevacizumab in Reducing CNS Side Effects in Patients Who Have Undergone Radiation Therapy to the Brain for Primary Brain Tumor, Meningioma, or Head and Neck Cancer | completed | Phase 2 | 11 | National Cancer Institute (NCI)NIH | 1 | May 9, 2014 | clinicaltrials |
| NCT00597402 | Avastin in Combination With Radiation (XRT) & Temozolomide, Followed by Avastin, Temozolomide and Irinotecan for Glioblastoma (GBM) and Gliosarcomas | completed | Phase 2 | 125 | Duke UniversityOTHER | 1 | May 7, 2014 | clinicaltrials |
| NCT00575146 | Ketogenic Diet for Recurrent Glioblastoma(ERGO) | completed | Phase 1 | 20 | University Hospital TuebingenOTHER | 1 | May 2, 2014 | clinicaltrials |
| NCT00677716 | Dose Confirmation Study of Cotara for the Treatment of Glioblastoma Multiforme at First Relapse | completed | Phase 2 | 41 | Peregrine PharmaceuticalsINDUSTRY | 2 | Apr 24, 2014 | clinicaltrials |
| NCT00397072 | Epothilone in Recurrent Glioblastoma Patients | completed | Phase 2 | 15 | Fondazione I.R.C.C.S. Istituto Neurologico Carlo BestaOTHER | 1 | Apr 17, 2014 | clinicaltrials |
| NCT00979017 | Avastin/Temozolomide/Irinotecan for Unresectable/Multifocal Glioblastoma Multiforme | completed | Phase 2 | 41 | Katy PetersOTHER | 1 | Mar 19, 2014 | clinicaltrials |
| NCT00657267 | Dose-Intense Temozolomide in Recurrent Glioblastoma | completed | Phase 2 | 58 | Patrick Y. Wen, MDOTHER | 1 | Mar 14, 2014 | clinicaltrials |
| NCT00611325 | Phase II Avastin + Bortezomib for Patients With Recurrent Malignant Glioma | completed | Phase 2 | 56 | Duke UniversityOTHER | 1 | Mar 12, 2014 | clinicaltrials |
| NCT00337883 | A Study of the Safety and Efficacy of Tarceva in Patients With First Relapse of Grade IV Glioma (Glioblastoma Multiforme) | completed | Phase 2 | 110 | Genentech, Inc.INDUSTRY | 0 | Mar 4, 2014 | clinicaltrials |
| NCT02047058 | Treatment Response and Prognosis in Glioma Patients: Q Cell and Its Biological Characteristics | unknown | — | 240 | Nanfang Hospital, Southern Medical UniversityOTHER | 1 | Jan 28, 2014 | clinicaltrials |
| NCT01854099 | Peptide Vaccine for Glioblastoma Against Cytomegalovirus Antigens(PERFORMANCE) | withdrawn | Phase 1 | 0 | University of FloridaOTHER | 0 | Jan 14, 2014 | clinicaltrials |
Data updated 23 days agoSource updated Mar 11, 2015source: clinicaltrials